Literature DB >> 25061056

A therapeutic approach for senile dementias: neuroangiogenesis.

Charles T Ambrose1.   

Abstract

Alzheimer's disease (AD) and related senile dementias (SDs) represent a growing medical and economic crisis in this country. Apart from cautioning persons about risk factors, no practical, effective therapy is currently available. Much of the recent research in AD has been based on the amyloid cascade theory. Another approach assumes a vascular basis for SDs. This paper presents evidence from a score of studies that cerebral capillary density (CCD) declines during old age in animals and people as well as in AD. Neuroangiogenic (NAG) factors initiate and maintain capillaries in the brain. Thus a waning level of these factors and the ensuing declining CCD would lead to local areas of reduced oxygen and glucose and result in impaired synaptic and neuronal function. The NAG hypothesis developed here proposes that the age-linked decline in CCD is a terminal condition in SDs, including many cases of AD. This age-linked decline is independent of any other of the various pathologies proposed as causing AD and listed in Table 1. Waning NAG factors would render the SDs a deficiency condition, somewhat like falling androgen levels in aging males. A logical corollary of this hypothesis is that chronic replacement therapy with recombinant forms of NAG factors may arrest the age-linked decline in CCD and prevent further loss of memory and mental deterioration. A transnasal route of therapy seems the most practical one for general use in the large aging populations.

Entities:  

Keywords:  Alzheimer's disease; cerebral capillary density; cognitive impairment; neuroangiogenesis; senile dementia

Mesh:

Substances:

Year:  2015        PMID: 25061056     DOI: 10.3233/JAD-140498

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  6 in total

1.  Epidermal growth factor prevents oligomeric amyloid-β induced angiogenesis deficits in vitro.

Authors:  Kevin P Koster; Riya Thomas; Alan W J Morris; Leon M Tai
Journal:  J Cereb Blood Flow Metab       Date:  2016-09-15       Impact factor: 6.200

2.  In Vitro Assays to Assess Blood-brain Barrier Mesh-like Vessel Formation and Disruption.

Authors:  Riya Thomas; Kazandra Diaz; Kevin P Koster; Leon M Tai
Journal:  J Vis Exp       Date:  2017-06-20       Impact factor: 1.355

3.  The Roles of Long-Term Hyperhomocysteinemia and Micronutrient Supplementation in the AppNL-G-F Model of Alzheimer's Disease.

Authors:  Hendrik Nieraad; Natasja de Bruin; Olga Arne; Martine C J Hofmann; Nina Pannwitz; Eduard Resch; Sonja Luckhardt; Ann-Kathrin Schneider; Sandra Trautmann; Yannick Schreiber; Robert Gurke; Michael J Parnham; Uwe Till; Gerd Geisslinger
Journal:  Front Aging Neurosci       Date:  2022-04-26       Impact factor: 5.702

4.  Effects of Intermittent Hypoxia-Hyperoxia on Performance- and Health-Related Outcomes in Humans: A Systematic Review.

Authors:  Tom Behrendt; Robert Bielitzki; Martin Behrens; Fabian Herold; Lutz Schega
Journal:  Sports Med Open       Date:  2022-05-31

5.  Intermittent hypoxia training protects cerebrovascular function in Alzheimer's disease.

Authors:  Eugenia B Manukhina; H Fred Downey; Xiangrong Shi; Robert T Mallet
Journal:  Exp Biol Med (Maywood)       Date:  2016-05-10

6.  Alzheimer's disease can be treated: Why the delay?

Authors:  Harry S Goldsmith
Journal:  Surg Neurol Int       Date:  2017-07-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.